Breast carcinomas occurring in young women (< 35 years) are different. by Walker, R. A. et al.
British Journal of Cancer (1996) 74, 1796-1800
©D) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Breast carcinomas occurring in young women (<35 years) are different
RA Walker, E Lees, M'B Webb and SJ Dearing
Breast Cancer Research Unit, University ofLeicester, Glenfield Hospital, Clinical Sciences, Groby Road, Leicester LE3 9QP, UK.
Summary One hundred and sixty-three breast carcinomas occurring in women aged between 26 and 44 years
were examined for pathological features, oestrogen and progesterone receptor status, proliferation as
determined by Ki-67 labelling and the presence ofc-erbB-2 and p53 protein, and were compared with a control
group of carcinomas from women in the 50-67 years age group. Carcinomas occurring in women aged under
35 years had a significantly high incidence of being poorly differentiated and of having high proliferation rates.
This group also had a significantly high incidence of p53 protein staining. Carcinomas in the under 30 years
age group had a lower incidence of oestrogen and progesterone receptor positivity. No differences were found
in c-erbB-2-positive staining between the groups. Infiltrating lobular carcinomas were only identified in women
aged 40 years and over. There was a higher incidence of a family history in the 35-44 years age group (18%)
than in the under 35 years age group (11%). Breast carcinomas occurring in women aged under 35 years are
more aggressive. An important finding is the high incidence of p53 positivity, which may indicate genetic
instability.
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There is evidence from several studies that women who
develop breast cancer at a young age (either 30 years and less
or 34 years and less) have lower survival rates than older
patients (Wallgren et al., 1977; Ribeiro and Swindell, 1981;
Noyes et al., 1982; Adami et al., 1986; Host and Lund, 1986;
Sant et al., 1991; de la Rochefordiere et al., 1993; Bonnier et
al., 1995; Chung et al., 1996). The findings have not differed
over a 25 year time span and have been reported from
different countries. Several publications have suggested that
the poorer prognosis may be related to the biological nature
of the tumour (Adami et al., 1986; Host and Lund, 1986; de
la Rochefordiere et al. 1993; Chung et al., 1996). Pillers
(1992) combined data on histological grading from two
centres and found that there was a higher frequency ofpoorly
differentiated carcinomas in the aged 34 years and under
group.
The presence or absence of various markers is associated
with poorer prognosis, e.g. the overexpression of c-erbB-2
oncoprotein (Walker et al., 1989; Gullick et al., 1991),
expression of p53 protein (Thor et al., 1992; Barnes et al.,
1993) and lack of oestrogen and progesterone receptor
(Foekens et al., 1989; Reiner et al., 1990). Higher levels of
proliferation as determined by Ki-67 labelling are associated
with poorer prognosis (Railo et al., 1993).
In order to determine whether there is a difference in the
biological nature of breast carcinomas arising in younger
women, a series has been studied for a variety of markers as
well as pathological features.
Materials and methods
Patients
One hundred and fifty-eight cases of invasive carcinomas
were identified from the pathology files of Leicester Royal
Infirmary and Glenfield Hospital, UK, and five cases were
provided by Alexandra Hospital, Redditch, UK, totalling
163. Cases who had received chemotherapy and/or radio-
therapy before excision of the tumour were excluded, as this
may modify the immunostaining and grading. Therefore,
there were no cases included which were considered clinically
to be inflammatory carcinomas. All were in the age range
26-44 years, with 18 between the ages of 26 and 29 years, 30
between 30 and 34 years, 40 between 35 and 39 years and 75
between 40 and 44 years. Node status was known for 150
cases, with 84 being node-positive and 66 being node-
negative. Information about family history was available
for 143 cases. A group consisting of 70 symptomatic
carcinomas from women aged 50-67 years for whom all
marker data were available was used for comparison. Data
on this group have previously been reported (Rajakariar and
Walker, 1995).
Pathology
Representative blocks from each case were fixed in 4%
formaldehyde in saline and processed through to paraffin
wax. Haematoxylin and eosin-stained sections were evaluated
for type of carcinoma using the criteria published in the
National Health Service (NHS) Breast Screening Guidelines
(1990). Infiltrating ductal carcinomas were graded using the
modified Bloom and Richardson criteria (Elston and Ellis,
1991), as recommended in the NHS Breast Screening
Guidelines and in the guidelines of the Association of
Directors of Anatomic and Surgical Pathology (1996).
Immunohistochemistry
The following antibodies were employed:
(1) Anti-oestrogen receptor mouse monoclonal antibody
(1D5) (Dako), which reacts with the N-terminal domain
of the receptor. This antibody has been compared with
Abbott H222 antibody applied to frozen and fixed tissue
and been shown to give similar results when antigen
retrieval is employed (Goulding et al., 1995, unpublished
observation).
(2) Anti-progesterone receptor mouse monoclonal antibody
(NCL-PgR) from Novocastra.
(3) MIB-1 mouse monoclonal antibody against the Ki-67
antigen (binding site) (Cattoretti et al., 1992).
(4) Polyclonal rabbit anti-p53 antiserum (CM1) (Novocastra).
(5) Mouse monoclonal anti-c-erbB-2 antibody (NCL CBl1)
from Novocastra. All secondary reagents were from
Dako.
ER, PgR and MIB-1 Formalin-fixed, paraffin-embedded
sections were mounted onto slides coated with Silane (3-
aminopropyltriethoxysilane, BDH) and immersed in 10 mM
citric acid buffer, pH 6.0. For ER and MIB-1, the sections
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1996were exposed to three cycles, each of 5 min, of microwave
irradiation using an 800 W microwave on maximum power.
For PgR, two cycles were used. The antibodies were applied
as follows: ID5, 1:100 dilution in Tris-buffered saline pH 7.4;
NCL PgR, 1:70 dilution; MIB-1, 1:50 dilution; all for 18 h at
4°C. Biotinylated rabbit anti-mouse immunoglobulin anti-
serum followed by streptavidin peroxidase was the detection
system and peroxidase was localised using diaminobenzi-
dine-hydrogen peroxide.
c-erbB-2 and p53 The antibody NCL CB 11 was applied at
1:80 for 18 h at 4°C, and was followed by biotinylated rabbit
anti-mouse immunoglobulin antiserum and streptavidin
peroxidase, as above. CM1 was applied at 1:100 for 18 h at
4°C and was followed by biotinylated swine anti-rabbit
immunoglobulin antiserum and streptavidin peroxidase, with
diaminobenzidine-hydrogen peroxide localisation. Controls
were present in all instances with the omission of the primary
antibody and the inclusion of a known positive in each
staining batch.
Evaluation Oestrogen and progesterone receptor reactivity
was categorised as negative, or as having < 10%, 10-25%,
25-50%, 50-75% and >75% positive cells, with 10% being
the cut-off point between positive and negative, as described
previously (Rajakariar and Walker, 1995). For p53, the
percentage of stained nuclei was determined with a minimum
of 500 cells being counted; more than 20% of cells having
moderate or strong staining was considered to be positive
staining. Membrane staining of the majority of tumour cells
was considered positive for c-erbB-2. The Ki-67 (MIBI) index
was assessed by counting a minimum of 500 nuclei and
calculating the percentage of stained nuclei. The results were
categorised into low (<10% positive cells), medium (10-
19%) and high (>20%) scores.
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Results
Pathologicalfeatures
The findings for type, grade and node status for the four
categories of young breast cancers and the control group are
given in Table I. There were no specialised carcinomas in the
34 years and under age groups, and no infiltrating lobular
carcinomas in those patients aged 39 years and under. The
distribution of types in the 40-44 years age group was
similar to controls.
No well-differentiated infiltrating ductal carcinomas were
found in the 34 years and less age groups, whilst the
percentage of these in the other two groups and the control
was similar. Sixty-nine per cent of the carcinomas from
patients aged 34 years and under were poorly differentiated.
There was a significant difference in the differentiation of the
carcinomas of women aged 34 years and under compared
with those from women aged 35-44 years (0.02>P>0.01,
x2=8.11, 2 d.f.) and from women aged 50-67 years
(P<0.001, x2= 14.38, 2 d.f.) but not between women aged
35-44 years and 50-67 years (x2=4.5, 2 d.f.).
There was a higher incidence of node-positive cases in the
under 30 years age group but the numbers in this category
were small.
Immunohistochemistry
The overall results are shown in Table II.
There was a low incidence of oestrogen and progesterone
receptor-positive carcinomas in the aged under 30 years
group. There was no significant difference in the oestrogen
and progesterone receptor results between the under 35 years
and the 35-44 years age groups, between the under 35 years
and control age groups, and between the 35-44 years and
control groups.
Table I Histological characteristics of the young breast cancer patients and the control group
Young breast cancer patients Cotrol
25-29 years 30-34 years 35-39 years 40-44 years 50-67 years
Type
Infiltrating ductal 18/18 (100%) 30/30 (100%) 39/40 (97.5%) 62/75 (82.5%) 60/70 (85.5%)
Infiltrating lobular 0 0 0 8/75 (10.5%) 6/70 (8.5%)
Tubular 0 0 0 3/75 (4%) 1/70 (1.5%)
Mucinous 0 0 1/40 2/75 (3%) 0
Medullary 0 0 0 0 1/76 (1.5%)
Papillary 0 0 0 0 2/70 (3%)
Grade
I 0 0 6/39 (15%) 9/62 (14.5%) 9/60 (15%)
II 6/18 (33%) 9/30 (30%) 16/39 (41%) 17/62 (27.5%) 29/60 (48%)
III 12/18 (67%) 21/30 (70%) 17/39 (44%) 36/62 (58%) 22/60 (37%)
Node status
Positive 11/16 (69%) 12/26 (46%) 25/40 (62.5%) 36/68 (53%) 36/64 (55%)
Negative 5/16 (31%) 14/26 (54%) 15/40 (37.75%) 32/68 (47%) 28/64 (54%)
Table II Incidence of receptors, c-erbB-2, p53 and proliferation index in relation to age
Young breast cancer patients Cotrol
25-29 years 30-34 years 35-39 years 40-44 years 50-67 years
Oestrogen receptor
Positive 8.18 (44%) 17/30 (57%) 28/40 (70%) 37/5 (49%) 47/70 (67%)
Progesterone receptor
Positive 6/18 (33%) 11/30 (37%) 24/40 (60%) 31/75 (44%) 34/70 (48.5%)
C-erbB-2
Positive 4/18 (22%) 6/30 (20%) 9/40 (22.5%) 13/75 (17%) 12/70 (17%)
p53
Positive 12/18 (67%) 16/30 (53%) 18/40 (45%) 30/75 (40%) 26/70 (37%)
Proliferation
Low 1/18 (6%) 6/30 (20%) 17/40 (42.5%) 25/75 (33%) 35/70 (50%)
Medium 4/18 (22%) 4/30 (13%) 7/40 (17.5%) 14/75 (17%) 7/70 (10%)
High 13/18 (72%) 20/30 (67%) 16/40 (40%) 36/75 (50%) 28/70 (40%)Breast carcinomas in young women
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The range of c-erbB-2 positivity was 17.0-22.5%, and
there were no significant differences between the different age
groups.
The highest incidence of detecting p53 was in the under 30
years age group (67%) (Figure 1), with a decreasing incidence
with increasing age (Figure 2). There was a significant
difference between the under 35 years age group and the
control group (X2=5.09, 1 d.f., 0.025>P>0.02), and between
the under 35 years and the 35 -44 years age groups (X2 =4.27,
1 d.f., 0.05>P>0.025) but not between the 35-44 years age
group and the control group.
Significant differences were found between the under 35
years age group and the control group for MIB-1 indices
(Z2=15.33, 2 d.f., P<0.001), with a higher incidence of high
proliferation rates in the younger group. Differences in
proliferation were also found between the under 35 years
age group and the 35-44 years group (x2=9.17, 2 d.f.,
P=0.01), but not between the latter group and the control
cases.
Relationship to Jamily history
Information about family history was known for 143 of the
women aged 44 years and younger: for 13 of the 18 women
aged under 30 years, for 24 of the 30 women aged 30 -34
years, for 38 of the 40 women aged 35-39 years and for 68
of the 75 women aged 40-44 years.
Two of the women under 30 years of age had a family
history (150%), one who had a mother affected at age 43 years
and the other whose mother was affected at age 53 years. The
carcinoma from the former case was moderately differen-
tiated and p53-positive, and that from the latter was poorly
differentiated and p53-positive. Only two women between 30
and 34 years had a family history (8%), involving an aunt
(premenopausal) in one case and a sister in the other. Both
carcinomas were poorly differentiated and p53 positive.
The incidence of family history was higher in the 35-39
years age group (18.4%) and the 40-44 years age group
(17.6%). Five women in the 35-39 years age group had a
mother affected premenopausally, one woman had an aunt
and a cousin affected and another had an aunt affected. Four
carcinomas were moderately differentiated, three were poorly
Figure 1 High power view of p53 staining in a poorly
differentiated carcinoma from a 26-year-old woman.
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Figure 2 Percentage of cases with evidence of p53 staining in
relation to age.
differentiated infiltrating ductal carcinomas and three were
p53-positive. Six of the women in the 40-44 years age group
had more than one family member affected, another two
women had mothers who were affected premenopausally. Ten
carcinomas were infiltrating ductal (one grade I, three grade
II, six grade III), one was a tubular carcinoma and another
was an infiltrating lobular carcinoma. p53 was detected in
four cases, a similar incidence to this age group overall.
Discussion
The study has shown that although there clearly are
differences in the carcinomas arising in women aged under
35 years, the carcinomas arising in women aged 35-44 years
are not significantly different from those occurring in women
aged 50-67 years. This emphasises the importance of the
subdivision of the under 50 years age group in any studies
that consider prognostic factors.
The differences in the carcinomas encompass both
pathological and biological features, although the two are
probably related. The high incidence of poorly differentiated
carcinomas in the under 35 years age group has been
reported by others (Pillers, 1992). It is striking that no well-
differentiated carcinomas were found in this age group and
that the differentiation of carcinomas in the 35 and over age
group was not significantly different from the older age
group. The 35-44 years age group had a higher incidence of
family history than the under 35 years age group and showed
no particular relationship to tumour type, grade and p53
status.
Both oestrogen receptor status and proliferation correlate
with differentiation. The presence of oestrogen receptor is
associated with better differentiation (Bruun Rasmussen et
al., 1981). It is therefore not surprising that there is a low
incidence of oestrogen receptor positivity in the 29 years and
younger age group. This has also been reported by Albain et
al. (1994). However, 57% of the carcinomas in the 30-34
years age group were oestrogen receptor positive, a value not
significantly different from the other age groups. This
suggests that there are other factors determining the
oestrogen receptor status as 70% of carcinomas in this
group were poorly differentiated. Proliferation as determined
by Ki-67 antigen detection relates to tumour differentiation
(Walker and Camplejohn, 1988), and high levels of Ki-67
labelling were seen in the two age groups with a high
incidence of poorer differentiation. A high S-phase fraction
was found in 60% or more of carcinomas from women 35
years and younger (Albain et al., 1994), which is similar to
the findings in this study for Ki-67.
Infiltrating lobular carcinomas were only identified in
women aged 40 years or more. Marcus et al. (1994) have
reviewed the literature with regard to the pathology of early
onset of breast carcinoma. They considered that there was aBreast carcinomas in young women
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significant trend for less invasive lobular carcinoma in the
younger age group and noted the effect to be most prominent
in the 20-29 year age group. However, such a clear cut-off
point at 40 years has not been reported by others.
Although c-erbB-2 expression has been related to poorer
differentiation (Walker et al., 1989; Allred et al., 1992), there
was no difference in expression between the different age
groups and the control. Allred et al. (1992) found a higher
incidence of c-erbB-2 expression in cases of infiltrating ductal
carcinoma with associated ductal carcinoma in situ, and
which they found more frequently in a younger age group.
However, their group (Albain et al., 1994) found no
significant difference in expression across age groups.
Apart from differentiation and proliferation, the one
marker which was significantly different between the under
35 years age group and the other age groups was p53, with a
high incidence of 67% positive cases in the under 30 years
age group. The presence of p53 protein does not necessarily
imply that there is a mutation as other factors can lead to
stabilisation and hence reactivity (Wynford-Thomas, 1992).
Both p53 protein staining and mutation have been associated
with poorer differentiation and oestrogen and progesterone
receptor-negative tumours (Walker et al., 1991; Mazars et al.,
1992; Thor et al., 1992; Barnes et al., 1993; Jacquemier et al.,
1994). When age has been considered, it has usually involved
the subdivision of women into under or over 50 years of age,
and no significant difference has been found. Caleffi et al.
(1994) did find a significantly higher incidence of p53
mutations in younger women, using 45 years of age as the
cut-off point. Albain et al. (1994) also reported a striking
incidence of p53 protein in the 35 years and under age group.
Several studies have implicated p53 protein in the G,-S
arrest which occurs in response to DNA damage (Kuerbitz et
al., 1992; Yin et al., 1992). p53 activates a Mr 21 000 protein
(Cip/WAF1/SDI) which inhibits the activity of cyclin-
dependent kinases and thus induces arrest in GI or apoptosis
(El-Deiry et al., 1994). Cells with abnormal p53 do not
activate p21 and do not show normal G, arrest which is
necessary for repair after exposure to DNA-damaging agents.
In a study of 183 breast carcinomas, Eyfjord et al. (1995)
found a significant association between p53 abnormalities
and genetic instability.
It will be of particular interest and importance to analyse
the breast carcinomas occurring in the young age group to
determine whether there are any common p53 abnormalities
and whether there are any associated DNA repair defects.
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